Abivax

Abivax Focuses on Developing Innovative Therapies to Modulate Immune Responses in Patients with Chronic Inflammatory Diseases by Leveraging the Body's Natural Regulatory Mechanisms. As a Clinical-Stage Company, Abivax is Currently Evaluating its Leading Drug Candidate, Obefazimod, for the Treatment of Adult Patients with Moderate to Severe Active Ulcerative Colitis, and is Preparing to Initiate a Phase 2a Clinical Trial of Obefazimod in Crohn’s Disease (“CD”) Patients, While Also Assessing Other Potential Inflammatory Indications. Abivax is Currently Evaluating its Lead Drug Candidate, Obefazimod, in a Phase 3 Clinical Trial for the Treatment of Adult Patients with Moderate to Severe Active Ulcerative Colitis (“UC”). Abivax is Also in the Planning Stages to Initiate a Phase 2a Clinical Trial of Obefazimod in Crohn’s Disease (“CD”) Patients, While Continuing to Evaluate Other Potential Inflammatory Indications.